Argenx
ARGX
#408
Rank
C$79.58 B
Marketcap
C$1,278
Share price
-0.63%
Change (1 day)
45.31%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2025 (TTM): C$12.46

According to Argenx 's latest financial reports the company's current EPS (TTM) is C$12.38. In 2024 the company made an earnings per share (EPS) of C$19.42 an increase over its 2023 EPS that were of C-$7.20.

EPS history for Argenx from 2011 to 2025

Annual EPS

Year EPS Change
2025 (TTM)C$12.46-35.84%
2024C$19.42-369.77%
2023C-$7.20-60.46%
2022C-$18.2163.33%
2021C-$11.15-40.37%
2020C-$18.70183.47%
2019C-$6.60123.09%
2018C-$2.9654.93%
2017C-$1.9114.07%
2016C-$1.6713.05%
2015C-$1.48-36.34%
2014C-$2.32209.04%
2013C-$0.75-33.99%
2012C-$1.14185.59%
2011C-$0.40